United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 10 mg - depression - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. childhood enuresis - may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute imipramine hydrochloride in patients receiving a monoamine oxidase inhibitor, as long

United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - ribavirin (unii: 49717awg6k) (ribavirin - unii:49717awg6k) - ribavirin 200 mg - ribavirin in combination with peginterferon alfa-2a is indicated for the treatment of patients 5 years of age and older with chronic hepatitis c (chc) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. the following points should be considered when initiating ribavirin combination therapy with peginterferon alfa-2a: ribavirin is contraindicated in: ribavirin and peginterferon alfa-2a combination therapy is contraindicated in patients with: teratogenic effects pregnancy: category x [see contraindications (4)] . ribavirin produced significant embryocidal and/or teratogenic effects in all animal species in which adequate studies have been conducted. malformations of the skull, palate, eye, jaw, limbs, skeleton, and gastrointestinal tract were noted. the incidence and severity of teratogenic effects increased with escalation of the drug dose. survival of fetuses and offspring was reduced [see contraindications (4) and warnings and precautions (5.1)] . in

United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - ribavirin (unii: 49717awg6k) (ribavirin - unii:49717awg6k) - ribavirin 200 mg - ribavirin capsules in combination with interferon alfa-2b (pegylated and nonpegylated) is indicated for the treatment of chronic hepatitis c (chc) in patients 3 years of age and older with compensated liver disease [see warnings and precautions (5.9, 5.10) , and use in specific populations (8.4) ]. the following points should be considered when initiating ribavirin combination therapy with peginterferon alfa-2b or interferon alfa-2b: ribavirin combination therapy is contraindicated in: pregnancy category x [see contraindications (4), warnings and precautions (5.1), and nonclinical toxicology (13.1) ]. treatment and posttreatment potential risk to the fetus ribavirin is known to accumulate in intracellular components from where it is cleared very slowly. it is not known whether ribavirin contained in sperm will exert a potential teratogenic effect upon fertilization of the ova. in a study in rats, it was concluded that dominant lethality was not induced by ribavirin at doses up to 200 mg/kg for 5 days (estimat

United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - quinidine gluconate 324 mg - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine gluconate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative meas

United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals - sulindac (unii: 184sns8vuh) (sulindac - unii:184sns8vuh) - sulindac 150 mg - carefully consider the potential benefits and risks of sulindac tablets and other treatment options before deciding to use sulindac tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). sulindac tablets are indicated for acute or long-term use in the relief of signs and symptoms of the following: - osteoarthritis - rheumatoid arthritis1 - ankylosing spondylitis - acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) - acute gouty arthritis sulindac tablets are contraindicated in patients with known hypersensitivity to sulindac or the excipients (see description ). sulindac tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings – anaphylactic/anaphylactoid reactions, and precautions – preexisting asthma

United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - felodipine (unii: ol961r6o2c) (felodipine - unii:ol961r6o2c) - felodipine 2.5 mg

United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - clonidine hydrochloride (unii: w76i6xxf06) (clonidine - unii:mn3l5rmn02) - clonidine hydrochloride 0.1 mg - clonidine hydrochloride tablets usp are indicated in the treatment of hypertension. clonidine hydrochloride tablets usp may be employed alone or concomitantly with other antihypertensive agents. clonidine hydrochloride tablets usp should not be used in patients with known hypersensitivity to clonidine (see precautions ). safety and effectiveness in pediatric patients have not been established in adequate and well-controlled trials (see warnings, withdrawal ).

United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - trihexyphenidyl hydrochloride (unii: ao61g82577) (trihexyphenidyl - unii:6rc5v8b7po) - trihexyphenidyl hydrochloride 2 mg - trihexyphenidyl hcl tablets are indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). it is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones.

United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals inc. - diphenhydramine hydrochloride (unii: tc2d6jad40) (diphenhydramine - unii:8gts82s83m) - diphenhydramine hydrochloride 25 mg - antihistamine temporarily relieves these symptoms of hay fever or other upper respiratory allergies: - runny nose - sneezing - itchy nose or throat - itchy, watery eyes - glaucoma - trouble urinating due to an enlarged prostate gland - a breathing problem such as emphysema or chronic bronchitis taking sedatives or tranquilizers

United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals inc. - ferrous sulfate (unii: 39r4tan1vt) (ferrous cation - unii:gw89581owr) - ferrous cation 325 mg - suggested use:  adults: one (1) tablet daily, preferably after meals or as directed by the doctor. children: as directed by the doctor.